Vaxart seeks shareholder nod for reverse stock split

Vaxart (VXRT), facing a 32% year-to-date stock decline and trading at $0.45, is urging shareholders to approve a reverse stock split to regain compliance with Nasdaq's minimum bid price rule; the company is burning through cash despite significant revenue growth and analysts anticipate a sales decline this year. Vaxart is also expanding its Phase 2b trial for an oral COVID-19 vaccine and has completed enrollment for its Phase 1 trial of a second-generation oral norovirus vaccine, with topline data expected in mid-2025, amid strategic cost reductions aimed at extending Vaxart’s cash runway into 2026.

Analysis

Vaxart, Inc. (VXRT), with a market capitalization of $102.6 million, is in a precarious position, evidenced by its stock trading at $0.45, a 32% year-to-date decline, prompting a shareholder vote on a reverse stock split to regain Nasdaq compliance. Despite a significant 433% revenue growth in the last twelve months, an InvestingPro analysis highlights that the company is rapidly burning through cash, and analysts anticipate a sales decline in the current year. Vaxart's balance sheet shows more cash than debt, but its current ratio of 0.64 indicates short-term obligations exceed liquid assets, a critical liquidity concern. Management is pursuing strategic cost reductions to extend the cash runway into 2026. On the development front, Vaxart is advancing its oral recombinant vaccine platform, with its Phase 2b COVID-19 vaccine trial expanding to 10,000 participants under a BARDA-funded initiative, and topline data from its Phase 1 second-generation oral norovirus vaccine trial expected in mid-2025. The company has also recently appointed a new CFO, Jeroen Grasman, and resolved a government stop work order on its COVID-19 vaccine trial. However, forward-looking statements carry inherent risks, and there is no assurance that Vaxart's strategic initiatives or clinical developments will yield successful outcomes.

Key Decisions for Investors

• Investors should closely monitor the outcome of the shareholder vote on the reverse stock split, as approval is critical for maintaining Nasdaq listing but often signals underlying financial pressures.
• Careful scrutiny of Vaxart's cash burn rate, its current ratio of 0.64, and the effectiveness of cost-reduction measures is warranted, especially given the anticipated sales decline despite recent high revenue growth.
• Upcoming clinical milestones, such as the mid-2025 norovirus vaccine data and progress in the expanded COVID-19 Phase 2b trial, represent potential catalysts but also carry significant clinical and financial risks inherent in early-stage biotech.
• Consider the implications of a potential sales decline forecasted by analysts against the backdrop of strong past revenue growth, suggesting a need for caution regarding the sustainability of Vaxart's financial performance without new revenue drivers or successful clinical advancements.